Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall Street rallies as chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices dive by more than 2% as inflation fears outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
Eagle Pharmaceuticals Reports Third Quarter 2021 Results
November 9, 2021 6:50 AM ESTQ3 2021 net loss was $0.43 per basic and diluted share and adjusted non-GAAP net income was $0.57 per basic and $0.56 per diluted share Expect to receive approval for Abbreviated New Drug Application (ANDA) for vasopressin; December 15, 2021 GDUFA date Received favorable district court decision that Eagles proposed vasopressin product does not infringe any of the patents Par asserted against Eagle Entered into worldwide licensing agreement for CAL02, a novel first-in-class antitoxin agent ready for Phase 2b/3 development for the treatment of severe bacterial pneumonia Licensed U.S. commercial rights to landiolol, a beta-1... More
